Quick Answer
Werewolf Therapeutics, Inc. reported Diluted EPS of $1.33 per share (loss) for fiscal year 2025.
Werewolf Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.33 | +18.4% |
| 2024 | -$1.63 | -55.2% |
| 2023 | -$1.05 | +43.5% |
| 2022 | -$1.86 | +83.0% |
| 2021 | -$10.94 | +61.0% |
| 2020 | -$28.08 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.36 | +5.3% | +10.0% |
| June 30, 2025 | -$0.40 | +7.0% | +0.0% |
| March 31, 2025 | -$0.40 | -2.6% | -5.3% |
| September 30, 2024 | -$0.38 | -65.2% | +11.6% |
| June 30, 2024 | -$0.43 | -207.1% | -10.3% |
| March 31, 2024 | -$0.39 | -14.7% | -69.6% |
| September 30, 2023 | -$0.23 | +42.5% | -64.3% |
| June 30, 2023 | -$0.14 | +73.6% | +58.8% |
- Werewolf Therapeutics, Inc. showed an increase of +18.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Werewolf Therapeutics, Inc.’s diluted eps has grown by 95.3% (from $28.08 per share (loss) to $1.33 per share (loss)).
- The most recent figure is from Werewolf Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: